ArticleClinical and experimental pediatrics2025
Assessment of natural killer cell subpopulations in pediatric patients with transfusion-dependent β-thalassemia major.
Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron overload is a hallmark complication in patients with transfusion-dependent β-thalassemia major, primarily resulting from ineffective erythropoiesis, repeated blood transfusions, and increased gastrointestinal iron absorption. This iron accumulation, reflected in elevated serum ferritin levels, has been implicated in immune dysregulation. Natural killer (NK) cells are a pivotal component of the innate immune system, known for their cytotoxic activity and cytokine secretion, particularly interferon-gamma (IFN-γ). Disruption in NK cell subsets may compromise immune surveillance and defense against infections in these patients. PURPOSE: To evaluate the distribution and function of NK cell subpopulations in pediatric patients with transfusion-dependent β-thalassemia major and explore their association with iron overload and immune dysfunction.
methodsSeventy-eight children were enrolled and divided into 2 groups: 43 pediatric patients with transfusion-dependent β-thalassemia major and 35 apparently healthy controls. NK cells and their subsets (CD56bright, CD56dim, CD56neg) were quantified using multicolor flow cytometry. Serum IFN-γ levels were measured to assess NK cell cytokine activity. Ferritin levels were used as a marker of iron overload.
resultsPatients showed a significant reduction in CD56bright and CD56dim NK cells compared to controls (P<0.001), indicating impaired NK-mediated immunity. Conversely, the CD56neg subset, associated with dysfunctional or altered NK cell phenotypes, was significantly elevated in patients (P<0.002). A strong negative correlation was observed between serum ferritin levels and CD56dim NK cells (P=0.003), suggesting that iron overload suppresses cytotoxic NK activity. Moreover, IFN-γ levels inversely correlated with CD56bright (P<0.001) and CD56dim (P=0.019) cells, but positively correlated with CD56neg cells, implicating this altered subset as a potential compensatory source of cytokine production.
conclusionHyperferritinemia in pediatric β-thalassemia major is linked to a dysregulated NK cell profile, marked by suppression of functional CD56bright and CD56dim subsets and expansion of the atypical CD56neg subset. These alterations may compromise innate immunity and contribute to increased infection risk. Our findings highlight the immunomodulatory impact of iron overload and underscore the clinical importance of monitoring NK cell dynamics in thalassemia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.